Voriconazole-induced neuropathy

被引：17

作者：

Aksoy, Firdevs ^{[1
]}

Akdogan, Elif ^{[2
]}

Aydin, Kemalettin ^{[1
]}

Yilmaz, Mustafa ^{[2
]}

Altunayoglu, Vildan ^{[3
]}

Sozen, Ebru Emel ^{[1
]}

Omay, Serdar Bedii ^{[2
]}

Koksal, Iftihar ^{[1
]}

机构：

[1] Karadeniz Tech Univ, Sch Med, Dept Infect Dis & Clin Microbiol, TR-61080 Trabzon, Turkey

[2] Karadeniz Tech Univ, Sch Med, Dept Hematol, TR-61080 Trabzon, Turkey

[3] Karadeniz Tech Univ, Sch Med, Dept Neurol, TR-61080 Trabzon, Turkey

来源：

CHEMOTHERAPY | 2008年 / 54卷 / 03期

关键词：

voriconazole; neuropathy; fungal infection;

D O I：

10.1159/000140466

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Background: Fungal infections are common and life threatening among immunosupressive patients. Rare side effects may occur related to the use of voriconazole, which is the drug of choice in invasive aspergillosis. Patients and Methods: Neuropathy was determined through clinical and electromyographic findings during the course of voriconazole therapy in 2 patients developing invasive aspergillosis. Results: Since examinations revealed no neuropathy capable of ascription to any other cause and improvement followed the cessation of the drug, this suggested that neuropathy may be linked to voriconazole use. Conclusion: Neuropathy may be seen as a side effect during voriconazole treatment. Voriconazole-induced side effects should be borne in mind and patients carefully monitored during its use. Copyright © 2008 S. Karger AG.

引用

页码：224 / 227

页数：4

共 15 条

[1] Defining opportunistic invasive fungal infections in immunocompromised patients with cancer and hematopoietic stem cell transplants: An international consensus [J].

Ascioglu, S ;

Rex, JH ;

de Pauw, B ;

Bennett, JE ;

Bille, J ;

Crokaert, F ;

Denning, DW ;

Donnelly, JP ;

Edwards, JE ;

Erjavec, Z ;

Fiere, D ;

Lortholary, O ;

Maertens, J ;

Meis, JF ;

Patterson, TF ;

Ritter, J ;

Selleslag, D ;

Shah, PM ;

Stevens, DA ;

Walsh, TJ .

CLINICAL INFECTIOUS DISEASES, 2002, 34 (01) :7-14

[2]

BOSCH EP, 2004, NEUROLOGY CLIN PRACT, P2299

[3] Antifungal drug resistance to azoles and polyenes [J].

Canuto, MM ;

Gutierrez, F .

LANCET INFECTIOUS DISEASES, 2002, 2 (09) :550-563

[4] The challenge of invasive fungal infection [J].

de Pauw, BE ;

Meunier, F .

CHEMOTHERAPY, 1999, 45 :1-14

[5]

Ghannoum MA, 2002, EUR J MED RES, V7, P242

[6] Voriconazole versus amphotericin B for primary therapy of invasive aspergillosis [J].

Herbrecht, R ;

Denning, DW ;

Patterson, TF ;

Bennett, JE ;

Greene, RE ;

Oestmann, JW ;

Kern, WV ;

Marr, KA ;

Ribaud, P ;

Lortholary, O ;

Sylvester, R ;

Rubin, RH ;

Wingard, JR ;

Stark, P ;

Durand, C ;

Caillot, D ;

Thiel, E ;

Chandrasekar, PH ;

Hodges, MR ;

Schlamm, HT ;

Troke, PF ;

de Pauw, B .

NEW ENGLAND JOURNAL OF MEDICINE, 2002, 347 (06) :408-415

[7]

Herbrecht Raoul, 2004, Expert Rev Anti Infect Ther, V2, P485, DOI 10.1586/14787210.2.4.485

[8]

Hoffman HL, 2002, EXPERT OPIN INV DRUG, V11, P409

[9] Voriconazole: A new triazole antifungal agent [J].

Johnson, LB ;

Kauffman, CA .

CLINICAL INFECTIOUS DISEASES, 2003, 36 (05) :630-637

[10] Intensive intravenous amphotericin B for prophylaxis of systemic fungal infections - Results of a prospective controlled pilot study in acute leukemia patients [J].

Karthaus, M ;

Doellmann, T ;

Klimasch, T ;

Elser, C ;

Rosenthal, C ;

Ganser, A ;

Heil, G .

CHEMOTHERAPY, 2000, 46 (04) :293-302

← 1 2 →